Ovarian carcinoma subtypes are different diseases: implications for biomarker studies M Köbel, SE Kalloger, N Boyd, S McKinney, E Mehl, C Palmer, S Leung, ... PLoS medicine 5 (12), e232, 2008 | 990 | 2008 |
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary SP Shah, M Köbel, J Senz, RD Morin, BA Clarke, KC Wiegand, G Leung, ... New England Journal of Medicine 360 (26), 2719-2729, 2009 | 880 | 2009 |
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma RGW Verhaak, P Tamayo, JY Yang, D Hubbard, H Zhang, CJ Creighton, ... The Journal of clinical investigation 123 (1), 2012 | 677 | 2012 |
Invasive epithelial ovarian cancer survival by histotype and disease stage LC Peres, KL Cushing-Haugen, M Köbel, HR Harris, A Berchuck, ... JNCI: Journal of the National Cancer Institute 111 (1), 60-68, 2019 | 498 | 2019 |
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study W Sieh, M Köbel, TA Longacre, DD Bowtell, A DeFazio, MT Goodman, ... The lancet oncology 14 (9), 853-862, 2013 | 482 | 2013 |
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors K Milne, M Köbel, SE Kalloger, RO Barnes, D Gao, CB Gilks, PH Watson, ... PloS one 4 (7), e6412, 2009 | 481 | 2009 |
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ... Nature genetics 49 (5), 680-691, 2017 | 455 | 2017 |
Differences in tumor type in low-stage versus high-stage ovarian carcinomas M Köbel, SE Kalloger, DG Huntsman, JL Santos, KD Swenerton, ... International Journal of Gynecological Pathology 29 (3), 203-211, 2010 | 426 | 2010 |
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma M Köbel, AM Piskorz, S Lee, S Lui, C LePage, F Marass, N Rosenfeld, ... The Journal of Pathology: Clinical Research 2 (4), 247-258, 2016 | 396 | 2016 |
Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility M Köbel, BM Ronnett, N Singh, RA Soslow, CB Gilks, WG McCluggage International journal of gynecological pathology 38, S123-S131, 2019 | 364 | 2019 |
Expression of cyclooxygenase 2 in human malignant melanoma C Denkert, M Köbel, S Berger, A Siegert, A Leclere, U Trefzer, ... Cancer research 61 (1), 303-308, 2001 | 350 | 2001 |
Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma C Denkert, KJ Winzer, BM Müller, W Weichert, S Pest, M Köbel, ... Cancer 97 (12), 2978-2987, 2003 | 338 | 2003 |
Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer EL Goode, MS Block, KR Kalli, RA Vierkant, W Chen, ZC Fogarty, ... JAMA oncology 3 (12), e173290-e173290, 2017 | 315 | 2017 |
Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010 MS Anglesio, MS Carey, M Köbel, H MacKay, DG Huntsman Gynecologic oncology 121 (2), 407-415, 2011 | 313 | 2011 |
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma C Denkert, M Köbel, S Pest, I Koch, S Berger, M Schwabe, A Siegert, ... The American journal of pathology 160 (3), 893-903, 2002 | 292 | 2002 |
The fallopian tube: primary site of most pelvic high-grade serous carcinomas S Salvador, B Gilks, M Köbel, D Huntsman, B Rosen, D Miller International Journal of Gynecologic Cancer 19 (1), 2009 | 279 | 2009 |
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma CB Gilks, DN Ionescu, SE Kalloger, M Köbel, J Irving, B Clarke, J Santos, ... Human pathology 39 (8), 1239-1251, 2008 | 273 | 2008 |
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma W Weichert, C Denkert, M Schmidt, V Gekeler, G Wolf, M Köbel, M Dietel, ... British journal of cancer 90 (4), 815-821, 2004 | 261 | 2004 |
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary M Köbel, SE Kalloger, J Carrick, D Huntsman, H Asad, E Oliva, ... The American journal of surgical pathology 33 (1), 14-21, 2009 | 258 | 2009 |
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations YR Hussein, B Weigelt, DA Levine, JK Schoolmeester, LN Dao, BL Balzer, ... Modern Pathology 28 (4), 505-514, 2015 | 247 | 2015 |